COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Estrogen Receptor-positive Breast Cancer
Interventions: DRUG: Aspirin|DRUG: Tamoxifen Pill|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Paclitaxel
Sponsor: University of Virginia